p53 dosage impedes KrasG12D- and KrasQ61R-mediated tumorigenesis
O. Le Roux, J. I. Everitt, C. M. Counter
The paper shows that increasing p53 dosage reduces tumor number and grade across multiple organs, regardless of Kras mutation type, and extends lifespan in a KrasG12D model.
bioRxiv · Sep 17, 2023Cancer Biology